RxDoctor Payments DataLook up a doctor →

Jeffrey Gordon, MD

Urology · Plymouth Meeting, PANPI 1124068044

Payments from drug & device makers

$50,100in general payments, 2019–2025

Across 412 payments — averaging $121.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$33K
  • Bayer$5K
  • Dendreon Pharmaceuticals LLC$2K
  • Johnson & Johnson$1K
  • Boston Scientific$1K
  • Astellas Pharma US Inc$1K
  • plus $6K from 32 others

What the payments were for

  • Consulting fees$4,30825%
  • Travel & lodging$1,89111%
  • Food & beverage$10,46862%
  • Education$3452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,100 in reported general payments places this provider in the 90th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$369,438
Medicare patients
990
Services billed
9,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix295$761,482
ErleadaApalutamide62$703,055
XtandiEnzalutamide45$520,955
NubeqaDarolutamide41$418,515
GemtesaVibegron142$83,334
MyrbetriqMirabegron137$78,013
Abiraterone Acetate42$52,830
Tamsulosin Hcl746$18,465
Finasteride330$7,251
Silodosin45$5,729
Alfuzosin Hcl ErAlfuzosin Hcl272$5,392
Testosterone25$5,292
Methenamine Hippurate49$4,876
Trospium Chloride ErTrospium Chloride22$3,112
Dutasteride28$1,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$491$844,815437 claims
Johnson & JohnsonErleada$1,391$703,05562 claims
Astellas Pharma US IncXtandi, Myrbetriq$1,098$598,968182 claims
BayerNubeqa$4,594$418,51541 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$145$52,83042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 596 urology providers in Pennsylvania.

Other urology in Plymouth Meeting

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →